At two years, the head-to-head comparison of ranibizumab with bevacizumab shows visual acuity with monthly treatment was slightly better than with as-needed
dosing, regardless of the drug.
Monthly treatment resulted in a mean improvement of about half a line better than as-needed dosing. Switching to as-needed treatment after one year of monthly treatment yielded outcomes nearly equal to those obtained with as-needed treatment for the full two years.